Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 01:15 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma
NCT00945269 · Fred Hutchinson Cancer Center · PHASE1/PHASE2 · terminated · last registry update 2022-11-15 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “ONTAK has been pulled off the market for further testing. Subsequently, EISAI will no longer be supporting clinical trials that utilize this drug.” | – | Registry record, Fred Hutchinson Cancer Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL2RA within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-11-07Results posted on the registry: M.D. Anderson Cancer Center, Aldesleukin + Allogeneic CD56-positive CD3-negative Natural Killer Cells (NCT01823198)
- 2023-11-01Also stopped (terminated): Jonsson Comprehensive Cancer Center, Aldesleukin + Busulfan (NCT03240861)
- 2023-09-21Also stopped (terminated): Fate Therapeutics, FT516 + Avelumab (NCT04551885)
- 2023-08-15Also stopped (withdrawn): University of Nebraska, a drug against IL2RA (NCT02409147)
- 2023-08-04Results posted on the registry: Albert Einstein College of Medicine, Aldesleukin + Anti-thyroglobulin mTCR-transduced Autologous Peripheral Blood Lymphocytes (NCT02774291)
- 2023-08-04Also stopped (terminated): Albert Einstein College of Medicine, Aldesleukin + Anti-thyroglobulin mTCR-transduced Autologous Peripheral Blood Lymphocytes (NCT02774291)
- 2023-08-03Also stopped (terminated): Rutgers, The State University of New Jersey, Aldesleukin + Pembrolizumab (NCT02748564)
- 2023-07-18Also stopped (terminated): CINJRegulatory, aldesleukin + ipilimumab (NCT02203604)
- 2023-06-18Results posted on the registry: CINJRegulatory, aldesleukin + ipilimumab (NCT02203604)
- 2023-05-15Results posted on the registry: Barbara Ann Karmanos Cancer Institute, Aldesleukin + Antibody Therapy (NCT02620865)
- 2023-03-21Results posted on the registry: City of Hope Medical Center, aldesleukin + filgrastim (NCT00534469)
- 2023-03-03Results posted on the registry: Masonic Cancer Center, University of Minnesota, Aldesleukin: All Patients + Nivolumab: Cohort 1 (Cutaneous) (NCT03850691)
- 2023-02-24Results posted on the registry: St. Jude Children's Research Hospital, cyclophosphamide + topotecan (NCT01857934)
- 2023-02-14Also stopped (withdrawn): Carman Giacomantonio, Interleukin-2 + Combination therapy Interleukin-2 and Bacillus Calmette Guerin (NCT03928275)
- 2023-02-09Results posted on the registry: Rutgers, The State University of New Jersey, Aldesleukin + Pembrolizumab (NCT02748564)
- 2023-02-01Results posted on the registry: Washington University School of Medicine, Fludarabine + Cyclophosphamide (NCT01898793)
- 2023-01-18Results posted on the registry: National Cancer Institute (NCI), Aldesleukin + Fludarabine (NCT01993719)
- 2022-11-30Phase 3 first posted: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Human umbilical cord mesenchymal stem cells + Interleukin-2 (NCT05631717)
- 2022-11-10Results posted on the registry: Fred Hutchinson Cancer Center, Aldesleukin + Cyclophosphamide (NCT01807182)
- 2022-11-04Also stopped (terminated): University of Cologne, antibody ch14.18 + GM-CSF (NCT02641782)
- 2022-09-29Results posted on the registry: University of California, Los Angeles, Basiliximab + Tacrolimus (NCT02123108)
- 2022-09-28Results posted on the registry: St. Jude Children's Research Hospital, dexamethasone + vincristine sulfate (NCT01700946)
- 2022-09-28Results posted on the registry: Case Western Reserve University, Recombinant Interleukin-2 (NCT03308786)
- 2022-09-28Also stopped (terminated): Case Western Reserve University, Recombinant Interleukin-2 (NCT03308786)
- 2022-08-31Also stopped (terminated): Centre Hospitalier Universitaire de Nice, Interleukin-2 (NCT01840046)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision